The poster, entitled Clinical Results About an Antimicrobial Solution in the Treatment of Infected Chronic Wounds, utilized Cutting & Harding infection criteria to evaluate the performance of the Microcyn Technology plus antibiotics versus a control group of povidone iodine plus antibiotics. Forty patients with infected wounds were randomized into the two groups; 20 each in the Microcyn and povidone iodine groups. Analyzed data included: pain (VAS), improvement/resolution of the clinical signs of infection, bad odour reduction, white blood cells count and duration of hospitalization.
The study, led by investigators E. Ricci, S. Astolfi and R. Cassino of the operative unit of vulnology at the San Luca Clinic in Turin, Italy, concluded that the Microcyn Technology showed better results than did the povidone iodine group in reduced number of days of hospitalization, reduction of clinical signs of infection and pain reduction.
Dr. Andres Gutierrez, director of medical affairs for Oculus Innovative Sciences, said, "This poster, along with the dozen other international clinical studies conducted to date, further supports the use of Microcyn Technology in the treatment of infected wounds. Encouraged by these data, we have initiated several study sites for the FDA Phase II trial in the treatment of mildly infected diabetic foot ulcers in the United States."
Microcyn Technology, with three 510k FDA clearances in the United States for cleaning, moistening, lubricating and debriding wounds, is not approved in the U.S. for treatment of infection.
Oculus Innovative Sciences is a bio pharmaceutical company that develops, manufactures and markets a family of Microcyn(R) Technology-based products intended to help prevent and treat infections in chronic and acute wounds. Oculus' platform technology, called Microcyn, is a non-irritating oxychlorine compound designed to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria, viruses, fungi and spores.
Oculus' principal operations are in Petaluma, California, and it conducts operations in Europe and Latin America through its wholly-owned subsidiaries, Oculus Innovative Sciences Netherlands B.V. and Oculus Technologies of Mexico, S.A. de C.V. Our website is www.oculusis.com.
Except for historical information herein, the matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are identified by the use of words such as "intended," "reduce," "reduction," and "designed," among others. These forward-looking statements are based on Oculus Innovative Sciences, Inc.'s current expectations. Investors are cautioned that such forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company's business including risks inherent in the development and commercialization of potential products, the risk that scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, the Company's future capital needs, and its ability to obtain additional funding and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission including the quarterly report on Form 10-Q for the quarter ended December 31, 2006. Oculus Innovative Sciences disclaims any obligation to update these forward-looking statements.
Oculus and Microcyn are trademarks or regis tered trademarks of Oculus Innovative Sciences, Inc.
Oculus Innovative Sciences, Inc.
Director of Public and Investor Relations
Dan McFadden, 425-753-2105
The Ruth Group
Sara Ephraim, 646-536-7002
Jason Rando / Janine McCargo, 646-536-7025 / 7033